Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (2848)	3/18/2013 10:46:24 PM
From: NP1986	Read Replies (1) \| Respond to of 3202

Given that the patient was on Jakafi for 3 months before developing PML, it's probably less likely to be due to Jakafi. If this turns out to be a real risk associated with Jakafi, I don't think it will affect its adoption for MF much. However, PV might be a different issue altogether. It may necessitate some kind of risk stratification as we've seen with Tysabri, and that would shrink the pool of patients considered eligible for Jakafi treatment. What would really suck is if this turns out to be an issue with the whole JAK class, which would impact more chronic indications as well. That said, this hasn't been an issue with tofacitinib, so there's probably little to be concerned about.